Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Trial Profile

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Mogamulizumab (Primary) ; Vorinostat
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms MAVORIC
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 08 Aug 2018 According to a Kyowa Hakko Kirin media release, Poteligeo has been approved by the FDA for the treatment of the two most common types of Cutaneous T-cell lymphoma [mycosis fungoides (MF) and Sezary syndrome (SS)] in previously treated patients (at least one prior systemic therapy) based on the data from this trial showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat.
    • 08 Aug 2018 According to a Kyowa Hakko Kirin media release, company is looking forward to the publication of MAVORIC's primary results and to ongoing scientific exchange within the medical and academic communities."
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top